HIGH-COST DRUGS ASSESSMENT: TWO-YEAR EXPERIENCE OF A HEALTH TECHNOLOGY ASSESSMENT UNIT IN A REFERRAL CANCER CENTER

被引：0
|
作者：
Quirland, C. [1 ]
Lahoz, D. [1 ]
Carreno-Leiton, D. [1 ]
Sanhueza, C. [2 ]
Gonzalez-Browne, C. [1 ]
机构：
[1] Arturo Lopez Perez Fdn, Dept Canc Res, Santiago, RM, Chile
[2] Arturo Lopez Perez Fdn, Pharmaceut Serv Dept, Santiago, Chile
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN167
引用
收藏
页码：S50 / S51
页数：2
相关论文
共 50 条
  • [41] Genetic assessment of hereditary breast and ovarian cancer in the Harris Health System: A five-year, single-center experience.
    Higashiyama, Nicole
    Bulsara, Shaun
    Hilsenbeck, Susan G.
    Tran, Tiffaney
    Brown, Ria
    Fang, Mary
    Sullivan, Cathy
    Garza, Georgiann
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Nangia, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] IMPACT OF HEALTH TECHNOLOGY ASSESSMENT REPORTS ON HOSPITAL DECISION MAKERS-10-YEAR INSIGHT FROM A HOSPITAL UNIT IN SHERBROOKE, CANADA: IMPACT OF HEALTH TECHNOLOGY ASSESSMENT ON HOSPITAL DECISIONS
    Poder, Thomas G.
    Bellemare, Christian A.
    Bedard, Suzanne K.
    Fisette, Jean-Francois
    Dagenais, Pierre
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2018, 34 (04) : 393 - 399
  • [43] Oncotyrol - Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research
    Siebert, Uwe
    Jahn, Beate
    Rochau, Ursula
    Schnell-Inderst, Petra
    Kisser, Agnes
    Hunger, Theresa
    Sroczynski, Gaby
    Muehlberger, Nikolai
    Willenbacher, Wolfgang
    Schnaiter, Simon
    Endel, Gottfried
    Huber, Lukas
    Gastl, Guenther
    ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2015, 109 (4-5): : 330 - 340
  • [44] Two-year Trends in Colorectal Cancer Screening After Switch to a High-deductible Health Plan
    Wharam, James Frank
    Graves, Amy Johnson
    Landon, Bruce E.
    Zhang, Fang
    Soumerai, Stephen B.
    Ross-Degnan, Dennis
    MEDICAL CARE, 2011, 49 (09) : 865 - 871
  • [45] Hospital-based Health Technology Assessment: the experience of Agostino Gemelli University Hospital's HTA Unit
    Catananti, Cesare
    Cicchetti, Americo
    Marchetti, Marco
    EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2005, 2 (02): : 23 - 28
  • [46] Is the quality of evidence in health technology assessment deteriorating over time? A case study on cancer drugs in Australia
    Gao, Yuan
    Laka, Mah
    Merlin, Tracy
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
  • [47] Availability and Coverage of New Drugs in 6 High-Income Countries With Health Technology Assessment Bodies
    Wouters, Olivier J.
    Naci, Huseyin
    Papanicolas, Irene
    JAMA INTERNAL MEDICINE, 2024, 184 (03) : 328 - 330
  • [48] Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience
    Higashiyama, Nicole
    Bulsara, Shaun
    Hilsenbeck, Susan
    Tran, Tiffaney
    Brown, Ria
    Fang, Mary
    Sullivan, Cathy
    Garza, Georgiann
    Shafaee, Maryam Nemati
    Osborne, C. Kent
    Rimawi, Mothaffar
    Nangia, Julie
    CANCER RESEARCH, 2022, 82 (04)
  • [49] THE INFLUENCE OF COST-EFFECTIVENESS ISSUES OF THE APPRAISED ORPHAN DRUGS ON RECOMMENDATIONS OF AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AHTAPOL)
    Ofierska-Sujkowska, G.
    Jagodzinska-Kalinowska, K.
    Matusewicz, W.
    VALUE IN HEALTH, 2011, 14 (03) : A21 - A21
  • [50] HEALTH TECHNOLOGY ASSESSMENT (HTA) FOR ORPHAN DRUGS IN COST-EFFECTIVENESS (CE) MARKETS: CURRENT DEVELOPMENT AND FUTURE TRENDS
    Zhang, A.
    Weisse, S.
    Chen, X.
    VALUE IN HEALTH, 2016, 19 (07) : A601 - A601
12345